Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial (Q38364028)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial |
scientific article |
Statements
1 reference
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial (English)
1 reference
1 reference
David R Gandara
1 reference
Grace K Dy
1 reference
Editta Baldini
1 reference
Naiyer A Rizvi
1 reference
Julien Mazières
1 reference
David Planchard
1 reference
Thomas E Stinchcombe
1 reference
Scott J Antonia
1 reference
Leora Horn
1 reference
Hervé Lena
1 reference
Elisa Minenza
1 reference
Bertrand Mennecier
1 reference
Gregory A Otterson
1 reference
Luis T Campos
1 reference
Benjamin P Levy
1 reference
Suresh G Nair
1 reference
Gérard Zalcman
1 reference
Jürgen Wolf
1 reference
Pierre-Jean Souquet
1 reference
Afshin Dowlati
1 reference
Rachel Sanborn
1 reference
Ariel Lopez-Chavez
1 reference
Christian Grohe
1 reference
Rudolf M Huber
1 reference
Christopher T Harbison
1 reference
Christine Baudelet
1 reference
Brian J Lestini
1 reference
Suresh S Ramalingam
1 reference
20 February 2015
1 reference
16
1 reference
3
1 reference
257-265
1 reference
Identifiers
1 reference